ArticleScientific reports2026
Plasma-activated solutions reverse chronic deltamethrin exposure induced intestinal injury via rebalancing redox homeostasis and counteracting cellular senescence.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Deltamethrin (DLM), a widely used pesticide, poses chronic exposure risks. Previous studies have shown its role in inducing intestinal mucosal barrier impairment. Meanwhile, plasma-activated solutions (PAS) ameliorate Dextran Sulfate Sodium (DSS)-induced colitis, primarily through the regulation of redox homeostasis. Building upon these findings, to further investigate the therapeutic potential of PAS against DLM-induced injury, we establish a chronic DLM exposure model in female BALB/c mice with concurrent free access to PAS. Intestinal tissues and serum are collected for H&E staining and measurement of serum inflammatory factors to assess inflammatory response. Immunofluorescence staining are used to detect intestinal injury and senescence. Reactive Oxygen Species (ROS) staining and glutathione (GSH) assays are performed to evaluate redox homeostasis. Results confirm that PAS effectively counteract chronic DLM-induced intestinal impairment, manifesting as restored body weight, decreased Disease Activity Index (DAI) scores, reduced apoptosis of intestinal epithelium and diminished inflammatory cell infiltration. To identify the key active component in PAS responsible for this therapeutic effect, A nitrogen-free PAS generator is used to produce nitric oxide-depleted PAS. Results show that after eight weeks of Nitro-Free PAS treatment, the therapeutic benefits are significantly weakened or disappeared. PAS mitigate chronic DLM induced intestinal impairment by rebalancing redox homeostasis, counteracting cellular senescence and restoring cell cycle progression. This therapeutic effect is mediated by reactive nitrogen species (RNS) within PAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.